Semaglutide and Breastfeeding: Pills, Shots and Evidence

The semaglutide injection and the semaglutide pill do not have the same breastfeeding evidence or labeling. A small study offers reassuring information about transfer of injected semaglutide into milk. Oral products raise a separate issue because they contain the absorption enhancer salcaprozate sodium, or SNAC.^1,2

For a parent deciding whether to start, continue or restart treatment, the useful discussion includes the exact product, why it is needed, the infant's age and feeding pattern, and whether nutrition and milk production are established. Neither “none was detected” nor “the manufacturer has limited data” answers that entire decision.

What the injection study actually measured

A 2024 study analyzed milk samples from eight women using weekly subcutaneous semaglutide, at doses from 0.25 to 1 mg. Samples were collected before and 12 and 24 hours after a dose. Semaglutide was not detected in those samples.³ That is a finding about the assay, doses, sampling times and participants; it does not mean investigators proved that no molecule can ever enter milk.

The infants were beyond the newborn stage and were not an exclusively breastfed newborn study population. Growth and development were reported by mothers, rather than established through a large controlled infant-safety trial. The paper also describes one maternal report of transient infant diarrhea and decreased appetite; that observation does not establish drug causation.³

Important gaps remain: newborn and premature infants, long-term outcomes, larger maternal doses such as standard Wegovy maintenance treatment, and sustained effects on milk production or nutritional quality. A low calculated exposure is not a guarantee covering those unstudied situations. LactMed's August 15, 2026 review summarizes the small injection study and notes the lack of published infant drug levels and milk-production data.²

Why tablets have a different warning

Wegovy's June 2026 prescribing information says that an oral-formulation lactation study found semaglutide below the quantification limit in human milk, but SNAC and/or its metabolites were present. Infant clearance may differ from adult clearance, raising concern about accumulation. The label advises against breastfeeding during Wegovy tablet treatment. The current Rybelsus/Ozempic tablet label also advises against breastfeeding.^1,4

The injected formulation does not contain that oral absorption enhancer. Its label calls for considering the benefits of breastfeeding, the mother's need for treatment and potential infant effects; it does not give a blanket endorsement. LactMed likewise distinguishes injectable from oral semaglutide.^1,2 Read the actual product name and formulation rather than relying on “semaglutide” alone. Our oral versus injectable comparison explains the broader differences.

Why the label and LactMed can sound inconsistent

The checked Wegovy injection label still describes an absence of human milk data, while LactMed incorporates the published eight-mother study. Both are relevant: the label sets out the manufacturer's prescribing information, and LactMed evaluates the available lactation literature.^1,2,3 It would be inaccurate to write either that no human study exists or that the study establishes safety for every breastfeeding family.

An infant's age, medical vulnerability and reliance on milk affect how a clinician interprets that limited evidence. So does the treatment goal: maintaining diabetes control is a different clinical need from beginning medication solely for postpartum weight reduction. Those considerations should guide an individual benefit-risk discussion rather than an automatic switch between products.

Nutrition deserves attention alongside drug transfer

Breastfeeding adds nutritional demands. CDC guidance notes that calorie needs and supplementation questions vary with factors such as activity, body size and whether feeding is exclusive or mixed.⁵ A plan should address adequate intake, not just a target rate of weight loss.

If treatment is chosen, discuss how to track maternal intake, infant feeding, growth and any change in milk supply. Nausea, vomiting or markedly reduced appetite may make that plan harder to follow; persistent symptoms need review. Semaglutide and dehydration covers a separate maternal safety concern. There is not enough evidence to promise that semaglutide either reduces milk supply or leaves it unchanged in every person.²

Questions that make the appointment useful

Bring the product, dose, reason for treatment, infant feeding pattern and any growth or supply concerns. Ask what alternatives meet the treatment goal, what monitoring is appropriate, and what change would trigger reassessment. Do not assume pumping and discarding milk for a few hours creates a proven safe window; the available study did not establish such a protocol.

Pregnancy planning requires another discussion, rather than applying breastfeeding conclusions to a fetus. Our semaglutide and pregnancy guide addresses that distinction. If diabetes treatment is the reason for considering medication, semaglutide and metformin provides context for discussing the rest of the regimen.